Severe Hypertriglyceridemia Market: High-Growth Opportunities for Investors to 2034 - DelveInsight

DelveInsight's "Severe Hypertriglyceridemia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Severe Hypertriglyceridemia, historical and forecasted epidemiology as well as the Severe Hypertriglyceridemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Severe Hypertriglyceridemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Severe Hypertriglyceridemia Market Forecast
https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Severe Hypertriglyceridemia Market Report:
• The Severe Hypertriglyceridemia market size was valued approximately USD 2,421 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In November 2025, Ionis intends to file a supplemental regulatory submission before year-end to broaden the indication of Tryngolza to include severe hypertriglyceridemia. If approved, analysts at William Blair believe the antisense therapy could be "transformational" for patients with this condition. In consecutive late-stage clinical trials involving individuals with severe hypertriglyceridemia, Ionis Pharmaceuticals' antisense oligonucleotide Tryngolza demonstrated substantial reductions in triglyceride levels and a meaningful decrease in acute pancreatitis events. These results strengthen the company's case for expanding the drug's label to cover this high-risk population.
• In March 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has launched an Expanded Access Program (EAP) to provide investigational plozasiran to eligible patients with familial chylomicronemia syndrome (FCS) outside of clinical trials. Additionally, the company will present final Phase 2 data from the double-blind segment of the SHASTA-2 study, which evaluated plozasiran in patients with severe hypertriglyceridemia.
• In 2023, the United States held the largest market share for severe hypertriglyceridemia, comprising about 58% of the total market size in the 7MM, in comparison to other key markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In 2023, Germany recorded the largest market size for severe hypertriglyceridemia among European countries, reaching approximately USD 180 million, whereas Spain had the smallest market size at around USD 100 million.
• In 2023, the market size for severe hypertriglyceridemia in Japan was estimated at approximately USD 324 million, representing 13% of the total market across the 7MM.
• The anticipated introduction of new therapies, including ARO-APOC3, is expected to impact the overall market size of severe hypertriglyceridemia in the coming years.
• In 2023, the total number of prevalent cases of Hypertriglyceridemia in the 7MM was 155 million, and this figure is anticipated to increase by 2034.
• The United States had the highest diagnosed prevalence of Hypertriglyceridemia among the 7MM countries. According to DelveInsight's estimates, it accounts for approximately 44% of the total diagnosed prevalent cases of hypertriglyceridemia in the 7MM.
• In 2023, the diagnosed prevalent cases of Severe Hypertriglyceridemia (SHTG) in the 7MM were approximately 3,495 thousand, with expectations for an increase during the forecast period.
• In 2023, Germany reported the highest number of diagnosed prevalent cases of Hypertriglyceridemia among European countries, with approximately 7 million cases, followed by the UK. Conversely, Spain had the lowest prevalence, with around 4 million cases.
• In 2023, within the 7MM, severe hypertriglyceridemia cases were classified by etiology. The diagnosed prevalent cases of primary and secondary severe hypertriglyceridemia were approximately 1,500 thousand and 1,980 thousand, respectively.
• In 2023, the EU4 and the UK reported approximately 1,388 thousand diagnosed prevalent cases of severe hypertriglyceridemia. Among these, Germany accounted for about 364 thousand cases, representing the highest number of diagnosed prevalent cases of severe hypertriglyceridemia in Europe.
• In 2023, Japan represented 16% of the total diagnosed prevalent cases of severe hypertriglyceridemia in the 7MM, with around 562 thousand cases.
• Key Severe Hypertriglyceridemia Companies: Amarin Corporation, Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., Hightide Therapeutics, AstraZeneca, Kowa Research Institute, Inc., Regeneron Pharmaceuticals, Mochida Pharmaceutical, NeuroBo Pharma, Arisaph Pharma, Acasti Pharma Inc., and others
• Key Severe Hypertriglyceridemia Therapies: VASCEPA/VAZKEPA, Plozasiran (ARO-APOC3), Olezarsen, Pegozafermin (BIO89-100), ARO-APOC3, HTD1801, omefas, K-877, evinacumab, Ethyl Icosapentate, Gemcabene, ARI-3037MO, CaPre, Epanova, and others
• The Severe Hypertriglyceridemia epidemiology based on gender analyzed that the severity‐specific data reveal the highest number of cases were observed in moderate level of HTG
• The Severe Hypertriglyceridemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Severe Hypertriglyceridemia pipeline products will significantly revolutionize the Severe Hypertriglyceridemia market dynamics.

Severe Hypertriglyceridemia Overview
Primary illnesses and secondary disorders are the two basic categories into which severe hypertriglyceridemia falls. Genetic illnesses fall under the category of main disorders, with secondary causes and other underlying conditions frequently contributing to the latter.

Get a Free sample for the Severe Hypertriglyceridemia Market Report:
https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Severe Hypertriglyceridemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Severe Hypertriglyceridemia Epidemiology Segmentation:
The Severe Hypertriglyceridemia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Severe Hypertriglyceridemia
• Prevalent Cases of Severe Hypertriglyceridemia by severity
• Gender-specific Prevalence of Severe Hypertriglyceridemia
• Diagnosed Cases of Episodic and Chronic Severe Hypertriglyceridemia

Download the report to understand which factors are driving Severe Hypertriglyceridemia epidemiology trends @ Severe Hypertriglyceridemia Epidemiology Forecast
https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Severe Hypertriglyceridemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Severe Hypertriglyceridemia market or expected to get launched during the study period. The analysis covers Severe Hypertriglyceridemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Severe Hypertriglyceridemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Severe Hypertriglyceridemia Therapies and Key Companies
• VASCEPA/VAZKEPA: Amarin Corporation
• Plozasiran (ARO-APOC3): Arrowhead Pharmaceuticals, Inc.
• Olezarsen: Ionis Pharmaceuticals
• Pegozafermin (BIO89-100): 89bio, Inc.
• ARO-APOC3: Arrowhead Pharmaceuticals, Inc.
• HTD1801: HightideTherapeutics
• omefas: AstraZeneca
• K-877: Kowa Research Institute, Inc.
• evinacumab: Regeneron Pharmaceuticals
• Ethyl Icosapentate: Mochida Pharmaceutical
• Gemcabene: NeuroBo Pharma
• ARI-3037MO: Arisaph Pharma
• CaPre: Acasti Pharma Inc.
• Epanova: AstraZeneca

Discover more about therapies set to grab major Severe Hypertriglyceridemia market share @ Severe Hypertriglyceridemia Treatment Market
https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Severe Hypertriglyceridemia Market Drivers
• Rising Prevalence of Metabolic Disorders: Increasing rates of obesity, type 2 diabetes, metabolic syndrome, and sedentary lifestyles are significantly contributing to the growing patient pool with severe hypertriglyceridemia (SHTG).
• Increased Risk of Acute Pancreatitis: Severe hypertriglyceridemia (≥500 mg/dL or ≥1000 mg/dL) is strongly associated with recurrent acute pancreatitis, driving urgent demand for effective triglyceride-lowering therapies.
• Advancements in Targeted Therapies: Development of novel agents such as APOC3 inhibitors, ANGPTL3 inhibitors, RNA-based therapies, and gene-silencing technologies is expanding treatment options beyond fibrates and omega-3 fatty acids.
• Growing Awareness and Improved Diagnosis: Enhanced lipid screening programs, better clinical guidelines, and physician education are leading to earlier detection and treatment initiation.

Severe Hypertriglyceridemia Market Barriers
• High Cost of Novel Biologic Therapies: Advanced therapies such as antisense oligonucleotides and monoclonal antibodies often come with premium pricing, limiting patient access and reimbursement coverage.
• Limited Long-Term Outcome Data: While triglyceride reduction is evident, long-term cardiovascular outcome benefits for some emerging therapies remain under investigation.
• Strict Regulatory Requirements: Demonstrating both triglyceride lowering and clinical event reduction can prolong clinical development timelines.
• Competition from Generic Therapies: Established treatments like fibrates and prescription omega-3 fatty acids offer lower-cost alternatives, impacting uptake of premium therapies.

Scope of the Severe Hypertriglyceridemia Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Severe Hypertriglyceridemia Companies: Amarin Corporation, Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., Hightide Therapeutics, AstraZeneca, Kowa Research Institute, Inc., Regeneron Pharmaceuticals, Mochida Pharmaceutical, NeuroBo Pharma, Arisaph Pharma, Acasti Pharma Inc., and others
• Key Severe Hypertriglyceridemia Therapies: VASCEPA/VAZKEPA, Plozasiran (ARO-APOC3), Olezarsen, Pegozafermin (BIO89-100), ARO-APOC3, HTD1801, omefas, K-877, evinacumab, Ethyl Icosapentate, Gemcabene, ARI-3037MO, CaPre, Epanova, and others
• Severe Hypertriglyceridemia Therapeutic Assessment: Severe Hypertriglyceridemia current marketed and Severe Hypertriglyceridemia emerging therapies
• Severe Hypertriglyceridemia Market Dynamics: Severe Hypertriglyceridemia market drivers and Severe Hypertriglyceridemia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Severe Hypertriglyceridemia Unmet Needs, KOL's views, Analyst's views, Severe Hypertriglyceridemia Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.